Treating Severe Pediatric Keratoconjunctivitis with Topical Cyclosporine A

Area of Science:

• Ophthalmology
• Pediatric Eye Care
• Immunology

Background:

• Chronic keratoconjunctivitis is less common in children, risking delayed diagnosis and treatment.
• Two frequent forms in children are hyperergic blepharokeratoconjunctivitis (hBKC) and vernal keratoconjunctivitis (VKC).
• These conditions can lead to long-term visual acuity loss from corneal opacity.

Purpose of the Study:

• To increase awareness of chronic keratoconjunctivitis diagnosis in children.
• To present an effective treatment plan for severe pediatric chronic keratoconjunctivitis.
• To highlight the benefits of topical cyclosporine A (CSA) for these conditions.

Main Methods:

• Review of clinical presentations of hBKC and VKC in children.
• Discussion of topical immunosuppressive and anti-inflammatory treatment strategies.
• Focus on the role and advantages of cyclosporine A (CSA) in managing severe cases.

Main Results:

• hBKC is associated with hordeolum history, blepharitis, and lower corneal neovascularization.
• VKC presents with upper eyelid changes and superior limbus involvement.
• Topical CSA offers steroid-sparing effects and reduces exacerbations.

Conclusions:

• Consistent, long-term topical immunosuppressive therapy, such as CSA, is essential for managing severe chronic keratoconjunctivitis in children.
• Treatment duration of at least one year is recommended to disrupt immunologic processes.
• Effective management preserves visual development and prevents amblyopia, scarring, and astigmatism.